[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: the placebo group will receive an intramuscular injection (in the deltoid muscle) consisting of buffer and adjuvant only, on days 0, 21, and 35", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: receiving 120 micrograms of RBD protein recombinant SARS-CoV-2 vaccine in days 0, 21, and 35; intramuscular (deltoid muscle)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PreventionIntervention group: receiving 80 micrograms of RBD protein recombinant SARS-CoV-2 vaccine in days 0, 21, and 35; intramuscular (deltoid muscle)", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "80 \u00b5g;3;Days0-21-35;IM", "treatment_id": 1920, "treatment_name": "Noora", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "120 \u00b5g;3;Days0-21-35;IM", "treatment_id": 1920, "treatment_name": "Noora", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]